News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SEEL new 52 Week low
SEEL new 52 week low
SEEL new 52 week low
SEEL new 52 week low
SEEL new 52 week low
Let's see this follow SNGX 
SEEL new 52 week low
SEEL new 52 week low
SEEL new 52 week low
SEEL new 52 week low
SEEL new 52 week low
SEEL new 52 week low
SEEL new 52 week low
SEEL new 52 week low
SELL new 52+ lo
SEEL new 52 week low
SEEL new 52 lo
SEEL 10Q due March 12
Pretty sad.
SEEL new 52 week low
|
Followers
|
245
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
30451
|
|
Created
|
09/14/05
|
Type
|
Free
|
| Moderators | |||
Seelos Therapeutics is exploring new ways to think about and treat central nervous system (CNS) disorders in neurological diseases and disorders and in rare diseases. Our trials are designed to further evaluate the safety and efficacy of our acquired assets. These come to Seelos with well characterized efficacy and safety, thereby avoiding much of the lengthy and burdensome process of preclinical R&D.
By working with clinically ready novel and reformulated compounds we will move from asset acquisition to meaningful data readouts in an expedited and efficient fashion. It is our goal to develop unique and disruptive therapies and approaches to improve treatment of large known diseases, offer new treatments for large unmet or recently characterized indications as well as advance therapies for orphan indications.
Our approach to this process will require development that is appropriate and efficient for a company our size in the scope of work each program requires in regards to trial size and duration.
We invite you to stay update on the progress of our assets in our clinical development programs.
AI
